YM Biosciences US Enrolls First Patient in Phase II Brain Cancer Trial
Posted on: Thursday, 14 February 2008, 12:00 CST
YM BioSciences US has enrolled the first patient in its Phase II trial investigating nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma or DIPG, a form of inoperable, treatment-resistant brain cancer.
The patient was treated at the M D Anderson Cancer Center under the care of Johannes Wolff. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR).
Eight leading US pediatric clinical centers and two Canadian centers will be participating in the single-arm trial, which is designed to enroll 44 patients with DIPG who will be treated with nimotuzumab as monotherapy. The primary endpoint of the current trial is Response Rate, with a target of 15%, and recruitment is expected to be completed within approximately 18 months.
Source: Datamonitor
Related Articles
- YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
- YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
- YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
- Ym Biosciences Announces Nimotuzumab Colorectal Cancer Trial First Cohort is Closed to Accrual
- Ym Biosciences Announces Positive Preliminary Results From Phase I/II Lung Cancer Trial of Nimotuzumab Combined With Radiation
- YM Biosciences Cleared to Start Brain Tumor Trial
- YM Bioscience's Cancer Drug Cleared for Extra Europe Trials
- YM BioSciences Enrolls First Patients in Colorectal Cancer Trial
- YM BioSciences Cleared to Initiate Clinical Trial of Nimotuzumab in Children With Inoperable Recurrent Brain Cancer
 |
 |
User Comments (0)
RSS Feeds